Syndax Pharmaceuticals Management
Management criteria checks 2/4
Syndax Pharmaceuticals' CEO is Michael Metzger, appointed in Feb 2022, has a tenure of 2.75 years. total yearly compensation is $9.13M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth $843.97K. The average tenure of the management team and the board of directors is 2.4 years and 8.3 years respectively.
Key information
Michael Metzger
Chief executive officer
US$9.1m
Total compensation
| CEO salary percentage | 7.4% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.06% |
| Management average tenure | 2.4yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully
Oct 14
Syndax Pharmaceuticals: Navigating Through A Pivotal Year
Sep 20Syndax: Gearing Up For Launches
Jun 21Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Jun 20Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Mar 28Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Mar 04Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?
Nov 20Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Sep 27Syndax Pharmaceuticals Q2 2022 Earnings Preview
Aug 07Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
Apr 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$297m |
| Jun 30 2024 | n/a | n/a | -US$264m |
| Mar 31 2024 | n/a | n/a | -US$241m |
| Dec 31 2023 | US$9m | US$678k | -US$209m |
| Sep 30 2023 | n/a | n/a | -US$176m |
| Jun 30 2023 | n/a | n/a | -US$160m |
| Mar 31 2023 | n/a | n/a | -US$153m |
| Dec 31 2022 | US$4m | US$640k | -US$149m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | US$818k |
| Mar 31 2022 | n/a | n/a | US$15m |
| Dec 31 2021 | US$3m | US$594k | US$25m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$91m |
| Mar 31 2021 | n/a | n/a | -US$86m |
| Dec 31 2020 | US$2m | US$577k | -US$77m |
| Sep 30 2020 | n/a | n/a | -US$71m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$3m | US$540k | -US$56m |
| Sep 30 2019 | n/a | n/a | -US$61m |
| Jun 30 2019 | n/a | n/a | -US$65m |
| Mar 31 2019 | n/a | n/a | -US$69m |
| Dec 31 2018 | US$2m | US$506k | -US$74m |
| Sep 30 2018 | n/a | n/a | -US$74m |
| Jun 30 2018 | n/a | n/a | -US$72m |
| Mar 31 2018 | n/a | n/a | -US$67m |
| Dec 31 2017 | US$1m | US$492k | -US$61m |
Compensation vs Market: Michael's total compensation ($USD9.13M) is above average for companies of similar size in the US market ($USD5.38M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Metzger (53 yo)
2.8yrs
Tenure
US$9,127,419
Compensation
Mr. Michael A. Metzger is a Director at Pyxis Oncology, Inc since June 10, 2024. Mr. Metzger has experience in the biopharmaceutical sector, is serving as Chief Executive Officer and as a member of the Boa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$9.13m | 0.062% $ 844.0k | |
| President | 1.6yrs | US$4.04m | 0.015% $ 209.4k | |
| CFO, Treasurer & Chief Accounting Officer | 2.4yrs | US$2.83m | 0.021% $ 281.1k | |
| Senior VP | 8.3yrs | US$2.59m | 0.051% $ 690.0k | |
| Chief Medical Officer | 2.7yrs | US$2.81m | 0.042% $ 576.3k | |
| Co-Founder & Chief Scientific Officer | 19.1yrs | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Vice President of Investor Relations & Communications | 2.4yrs | no data | no data | |
| Chief People Officer | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board & Chief Medical Officer | 1.9yrs | no data | no data |
2.4yrs
Average Tenure
55yo
Average Age
Experienced Management: SNDX's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$9.13m | 0.062% $ 844.0k | |
| Co-Founder | 8.3yrs | no data | no data | |
| Member of Scientific Advisory Board & Chief Medical Officer | 8.3yrs | no data | no data | |
| Independent Director | 7.7yrs | US$581.02k | 0.037% $ 510.4k | |
| Independent Director | 7.8yrs | US$575.59k | 0.037% $ 510.4k | |
| Independent Chairman | 15.9yrs | US$1.10m | 0.017% $ 230.2k | |
| Member of Scientific Advisory Board | 7.6yrs | US$23.05k | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.8yrs | no data | no data |
8.3yrs
Average Tenure
64yo
Average Age
Experienced Board: SNDX's board of directors are considered experienced (8.3 years average tenure).